Jazz Pharmaceuticals plc Announces New Executive Appointments

DUBLIN, Jan. 24, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced several senior management appointments that will strengthen and broaden the company's leadership team.

The appointments include:

• Suzanne Sawochka Hooper will join the company and will serve as general counsel and an executive officer following the upcoming retirement of Carol Gamble in March.  Ms. Hooper is currently a partner at Cooley LLP, where she has practiced corporate and securities law since 1996.  She has provided counsel to Jazz Pharmaceuticals for more than five years and was closely involved in the company's recent business combination with Azur Pharma.  She will be based in the Palo Alto office.
• Fintan Keegan becomes senior vice president of technical operations and will oversee the company's manufacturing, supply chain, quality and technical operations.  Mr. Keegan was previously with Azur Pharma since 2006.  He has over 27 years of experience in manufacturing and related technical operations and will be based in the Dublin headquarters.
• Eunan Maguire becomes senior vice president of strategy and corporate development, where he will focus on the company's efforts to further expand its product portfolio.  Mr. Maguire was a co-founder of Azur Pharma and was president of US operations, where he was responsible for commercial, medical, legal and administrative activities in the US.  He has over 15 years of industry experience and will be based in the Philadelphia office.

Additional members of the company's senior management team include: Russell Cox, senior vice president and chief commercial officer; Kathryn Falberg, senior vice president and chief financial officer; Jeffrey Tobias, M.D., senior vice president of research and development and chief medical officer; Heather McGaughey, vice president of human resources; and Robert McKague, vice president and chief compliance officer.

"One of our most important assets is our people, and I am thrilled to be working with a smart, strategic group, who not only have the capability, but also the passion to build Jazz Pharmaceuticals plc for the long term.  This team has the right skills and industry experience to drive continued success and address unmet medical needs of patients," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "I would also like to acknowledge Carol Gamble for her many important contributions to the company during the past nine years and her tremendous commitment to patients and to our mission."

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs.  The company has a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women's health.  The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%).

SOURCE Jazz Pharmaceuticals plc

Ami Knoefler, Executive Director, Investor Relations & Corporate Communications, Jazz Pharmaceuticals plc, International, + 353 1 638 1032, U.S., +-1-650-496-2947, ami.knoefler@jazzpharma.com